Total Funding
45
59
Total FundingGrant raised
Growth Score 45 in past quarter
-9 pts
Heat Score 59 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
118390
AivoCode is an emerging biotech focused on critical and highly prevalent diseases affecting the central nervous system
- Aman Mann: Co-Founder and CEO
- Sazid Hussain: Co-Founder & Chief Scientific Officer
About the Company
AivoCode Inc. is an emerging biotechnology company focused on critical neurological diseases such as brain injury, Alzheimer’s disease and other degenerative disorders. AivoCode’s technology is based on proprietary and unique peptides that specifically recognize molecular changes in brain injuries and neurodegenerative diseases. These peptides
enhance the delivery of a variety of therapeutics and diagnostic agents into affected regions of the brain and can also possesses intrinsic therapeutic properties. AivoCode’s technology development was funded entirely by non-dilutive federal grant funding.